<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The human double minute 2 (hdm2) oncogene is a negative regulator of the p53 gene </plain></SENT>
<SENT sid="1" pm="."><plain>Expression and alternative splicing of the hdm2 gene may contribute to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> development or progression </plain></SENT>
<SENT sid="2" pm="."><plain>This study aimed to determine the presence and identification of aberrant <z:chebi fb="2" ids="33699">mRNA</z:chebi> transcripts of hdm2 in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues and cell lines, and determine the nature of their association with clinicopathological characteristics and survival of patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A total of 69 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and corresponding <z:mpath ids='MPATH_458'>normal</z:mpath> tissue specimens and 10 <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines were recruited for polymerase chain reaction and DNA sequencing analyses of hdm2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Genomic DNA from these tissues and cells was also extracted for p53 gene mutation analysis </plain></SENT>
<SENT sid="5" pm="."><plain>The association of hdm2 fragmented transcripts and p53 gene mutation with clinicopathological data was then statistically analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In 62 cases (89.9%; 62 of 69) of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues the full-length hdm2 was amplified, whereas 7 cases had no hdm2 transcripts </plain></SENT>
<SENT sid="7" pm="."><plain>Thirty-two of 62 cases (51.6%) and 6 of 10 cell lines (60%) showed at least 1 hdm2 spliced variant </plain></SENT>
<SENT sid="8" pm="."><plain>A total of 4 hdm2 splicing variants were found in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues and cells, that is, lack of <z:chebi fb="9" ids="36976">nucleotides</z:chebi> between 157 and 292 bp in hdm2/1338, 81 to 901 bp in hdm2/707, 157 to 292, 407 to 505, and 668 to 901 bp in hdm2/1007, and 610 to 883 in hdm2/1200 </plain></SENT>
<SENT sid="9" pm="."><plain>Of these, hdm2/1338 is a novel hdm2 variant in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Mutation in p53 was detected in 21 cases (33.8%; 21 of 62) </plain></SENT>
<SENT sid="11" pm="."><plain>Although there was no association found between expression of hdm2 splicing variants and p53 gene mutations, expression of hdm2 splicing variants was associated with advanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage (P = .022) and distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P = .004) in <z:mp ids='MP_0002169'>wild-type</z:mp> p53 cases, and with poor survival of patients (P = .039) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The data from the current study provide the first evidence that hdm2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> is frequently mutated by alternative splicing in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and may play a role in colorectal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> or <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> </plain></SENT>
</text></document>